Encorafenib
- Generic Name
- Encorafenib
- Brand Names
- Braftovi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClFN7O4S
- CAS Number
- 1269440-17-6
- Unique Ingredient Identifier
- 8L7891MRB6
- Background
Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most fr...
- Indication
Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It is also indicated in combination with cetuximab for the treatment of adult patients with metastatic colorecta...
- Associated Conditions
- Metastatic Colorectal Cancer (CRC), Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Unresectable Melanoma
- Associated Therapies
- -
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT03878719
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Lombardy, Italy
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT03864042
- Locations
- 🇨🇦
Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
🇺🇸UC Irvine Health, Orange, California, United States
🇺🇸University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT03843775
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity), Commack, New York, United States
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 26
- Registration Number
- NCT03839342
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 95
- Registration Number
- NCT03693170
- Locations
- 🇫🇷
AP-HM CHU Timone, Marseille, France
🇫🇷ICO- Site René Gauducheau, Saint-Herblain, France
🇫🇷Hôpital Europeen Georges Pompidou, Paris, France
Melanoma Metastasized to the Brain and Steroids
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 80
- Registration Number
- NCT03563729
- Locations
- 🇩🇰
Herlev Universityhospital, Herlev, Hovedstaden, Denmark
🇩🇰Aarhus Universityhospital, Aarhus, Midt, Denmark
🇩🇰Odense Universityhospital, Odense, Syd, Denmark
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2024-11-12
- Target Recruit Count
- 14
- Registration Number
- NCT03543969
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 702
- Registration Number
- NCT02928224
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Investigational Drug Services, Westwood, Kansas, United States
🇧🇷Hospital do Olho, Salvador, Bahia, Brazil
🇦🇹DZU, Diagnose Zentrum Urania GmbH, Wien, Austria
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT02910700
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Prof. Dr. med. Dirk Schadendorf
- Target Recruit Count
- 16
- Registration Number
- NCT02902042
- Locations
- 🇩🇪
University Hospital Essen, Department of Dermatology, Skin Cancer Center, Essen, North Rhine-Westphalia, Germany
🇩🇪HELIOS Klinikum Krefeld, Krefeld, North Rhine-Westphalia, Germany
🇩🇪Universitätsklinikum Gießen und Marburg GmbH, Klinik für Dermatologie und Allergologie, Gießen, Hessen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.